New antibody therapy offers hope for thyroid eye disease patients who failed steroids
NCT ID NCT07152366
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This study tests a drug called tetuzumab (IBI311) in 96 adults with moderate-to-severe active thyroid eye disease (TAO) who did not respond well to steroids. The drug blocks a protein that fuels inflammation and tissue swelling behind the eyes. The main goals are to see if it reduces eye bulging and inflammation without serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.